Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : US Oncology(USON) -- Ignore unavailable to you. Want to Upgrade?

To: Gary Korn who wrote (18)	11/9/1999 10:01:00 PM
From: Gary Korn	Respond to of 75

REVENUE 1996 1997 1998 1999 MAR 40,750 70,396 187,637 249,214 JUN 47,374 79,525 204,744 266,412 SEP 53,701 82,293 118,263 277,789* DEC 63,635 89,626 125,126 Totals 205,460 321,840 635,770 793,415* Note: Units in Thousands of U.S. Dollars EARNINGS PER SHARE 1996 1997 1998 1999 MAR .090 .110 .140 .160 JUN .090 .120 .150 -.010 SEP .090 .120 .150 .150 DEC .100 .130 .160 Tot .370 .480 .600 .300 Gary Korn

To: Gary Korn who wrote (18)	11/10/1999 9:21:00 AM
From: Charlie Smith	Respond to of 75

Gary: The revenues have been increasing very well over time. Be careful, Gary. When you roll up an industry as AORI has done it's not revenue growth that's key, because you can continue to buy companies and basically print any revenue number you want. Focus on EBITDA growth instead. Not quite as promising for AORI on this score. Charlie